US/UK/Canada

Share

Contacts

  • Mark Waugh

    CEO


    +1 (260) 804-1342

    • Links

    Pick a time period -
    Tags ( Active)

    OssDsign appoints Adam McCollister as new Vice President of Sales

    OssDsign Appoints Adam McCollister as Vice President of Sales to Accelerate U.S. Growth of Catalyst PlatformUppsala, Sweden, June 25, 2026 – OssDsign AB (publ.), a leader in next-generation orthobiologic solutions that support the body’s natural healing capabilities, today announced Adam McCollister has joined the company as Vice President of Sales. Mr. McCollister will lead the Company’s U.S. sales strategy and execution, with a focus on accelerating adoption of OssDsign’s Catalyst nanosynthetic bone graft. Mr. McCollister brings years of experience in orthopaedic sales and commercial

    Annual General Meeting held in OssDsign AB

    On 9 June 2026, OssDsign AB (publ) held its annual general meeting for 2026. Below is a summary of the resolutions passed at the annual general meeting (complete information and documents regarding the decisions of the meeting are available on the company’s website www.ossdsign.com).The annual general meeting resolved: · to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2025; · that the company’s result shall be carried forward in new account and that no dividend shall be paid for

    OssDsign Catalyst® outperforms earlier-generation bone graft as a standalone treatment in trauma study

    Uppsala, June 3, 2026. OssDsign AB (publ.) today announces the publication of a new scientific article in The Journal of Bone and Mineral Research (JBMR). The preclinical study evaluated OssDsign Catalyst as a standalone bone graft in trauma, comparing it to an earlier-generation bone graft. The results show significantly more bone formation with OssDsign Catalyst at earlier timepoints, as well as clear evidence that the graft is naturally broken down and replaced by the body over time – reinforcing the superiority of fourth-generation synthetic bone grafts like OssDsign Catalyst.In the

    OssDsign AB announces updated proposal regarding board fees ahead of the annual general meeting 2026

    The nomination committee of OssDsign AB (publ) (“OssDsign” or the “Company”) has updated its proposal regarding board fees ahead of the annual general meeting on 9 June 2026. The updated proposal entails that fees for work within the audit committee are added in addition to the previously proposed board fees.The nomination committee has previously proposed that the fees payable to the board of directors for the period until the end of the next annual general meeting shall amount to a total of SEK 1,300,000, out of which SEK 400,000 shall be paid to the chairman and SEK 300,000 to each of

    Notice to attend the Annual General Meeting in OSSDSIGN AB

    The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the annual general meeting at 10:00 am on Tuesday 9 June 2026 at Setterwalls Advokatbyrå’s offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences 30 minutes before the opening of the meeting.The board of directors has decided, pursuant to Chapter 7, Section 4, Paragraph 2 of the Swedish Companies Act and the company’s articles of association, to apply the possibility of proxy collection in conjunction with the general meeting (see section Proxy collection below for more

    OssDsign AB (publ) publishes Q1 2026 interim report

    Reset: Laying the groundwork for accelerated growthOssDsign AB (publ) announces that the interim report for Q1 2026 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release. The Q1 2026 results will also be presented at an investor webcast today May 5th at 11:00 CEST. The webcast can be accessed via the following link: https://qcnl.tv/p/J21zZyaq3hj3uEnQwRNXOg 

    OssDsign provides pre-release update on Q1 2026 performance

    OssDsign AB (publ.) today announces that preliminary revenue for the period January – March, 2026 will be USD 4.035 million or SEK 36.880 million.  The company attributes these results to a lack of sales channel expansion in late 2025, departure of certain sales personnel, and temporary slowdowns in key accounts due to contract negotiations.According to preliminary data, sales of OssDsign Catalyst from January to March 2026 were USD 4.035 million, representing a decline of 3.6%, or SEK 36.880 million, representing a decline of 17.1%, compared to the same quarter in the previous year. The

    OssDsign AB (publ) publishes year-end report 2025

    Strong growth and real-world data set the stage for U.S. market expansionOssDsign AB (publ) announces that the year-end report for 2025 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release.  The year-end 2025 results will also be presented at an investor webcast today February 3rd at 11:00 CET. The webcast can be accessed via the following link: https://www.finwire.tv/webcast/ossdsign/q4-2025/ 

    OssDsign appoints Mark Waugh as new CEO

    Uppsala, Sweden, 10th December, 2025 - OssDsign AB (publ.) today announces the appointment of Mark Waugh as CEO, effective 1st January 2026. He most recently served as Senior Vice President - Commercial at Medacta USA and has extensive experience in sales, marketing and commercial operations across all major orthopedic segments in global markets, including the USA and Europe.Mark Waugh (MBA, B.S) brings over two decades of international leadership experience from organizations such as Smith & Nephew plc, Medtronic Sofamor Danek Inc, and, most recently, Medacta USA, part of Swiss company

    OssDsign strengthens its commercial footprint in the Western U.S. through new agreement with IDN

    Uppsala, Sweden, December 5, 2025. OssDsign AB (publ.) today announces that the company has signed an agreement with an IDN (Integrated Delivery Network) in the Western U.S. marking the company’s most significant opportunity for sales growth in the region to date.The agreement allows IDN member hospitals and clinics, at their discretion, to take advantage of special pricing and pre-negotiated terms for OssDsign's nanosynthetic bone graft OssDsign Catalyst®. Since entering the orthobiologics business late 2021, the company has had a natural gravity towards the Eastern U.S.; however, during

    OssDsign AB (publ) publishes Q3 2025 interim report

    Record breaking sales month and best quarterly EBIT resultOssDsign AB (publ) announces that the interim report for Q3 2025 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release. The Q3 2025 results will also be presented at an investor webcast today November 4th at 11:00 CET. The webcast can be accessed via the following link: https://www.finwire.tv/webcast/ossdsign/q3-2025/ or via the OssDsign website. The third quarter in figures · Net sales amounted to TSEK 44,020 (35,728), which translates to a growth

    Performance of OssDsign Catalyst® in a patient with post-traumatic ankle arthritis showcased in medical journal

    Uppsala, Sweden, September 2, 2025. OssDsign AB (publ.) today announces that a case study of OssDsign Catalyst® as a bone void filler to augment total ankle arthroplasty in a patient with post-traumatic ankle arthritis has been published in the Biomedical Journal of Scientific & Technical Research.The rationale for the use of Catalyst Bone Graft for this patient, in addition to its ease of handling for the surgeon, was related to its mechanism of action, which includes both endochondral and intram­embranous ossification. The authors conclude that at three months follow up, CT scans show

    OssDsign AB (publ) publishes Q2 2025 interim report

    Extraordinary real-world clinical data and strengthened balance sheet to launch new "ScaleToProfit” growth strategyOssDsign AB (publ) announces that the interim report for Q2 2025 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release. The Q2 2025 results will also be presented at an investor webcast today August 19th at 11:00 CET. The webcast can be accessed via the following link: https://www.finwire.tv/webcast/ossdsign/q2-2025/ or via the OssDsign website. The second quarter in figures · Net sales

    Exercise period starts in OssDsign’s long-term incentive warrant program 2022/2025, boosting the company’s cash position by up to SEK 10 million

    Uppsala, July 1, 2025. OssDsign AB (publ.) announces that the exercise period for the long-term incentive warrant program 2022/2025 starts today on July 1.Approximately 1.5 million warrants have been issued to board members, executives and employees as part of the long-term incentive program adopted at OssDsign’s Annual General Meeting in 2022. According to the program, warrants can be exercised to buy shares (1 share per warrant) between July and December 2025. If all warrants are converted to shares, the company will receive approximately SEK 10 million.   In conjunction with the

    OssDsign announces remarkable real-world results with 88.4% fusion rate in a highly complex patient cohort from the spinal fusion registry PROPEL

    Uppsala, June 26, 2025. OssDsign AB (publ.) today announces that the company has published one-year results from the first 108 patients in its prospective, multi-center, spinal fusion registry PROPEL. The results show an outstanding fusion rate of 88.4% in the real-world setting in a highly complex patient cohort, demonstrating that OssDsign Catalyst® shows strong performance even in challenging patient populations with high BMI, previous failed fusion surgeries, smokers, multi-level procedures and several comorbidities.“Typically, I would expect to see dramatically lower fusion rates for

    Annual General Meeting held in OssDsign AB

    11 June 2025. Today, the annual general meeting of 2025 was held in OssDsign AB (publ). Below is a summary of the resolutions passed at the annual general meeting (complete information and documents regarding the decisions of the meeting are available on the company’s website www.ossdsign.com).The annual general meeting resolved:  -        to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2024;   -        that the company’s result shall be carried forward in new account and that

    Revised proposal for election of the board of directors in OssDsign

    Uppsala, June 9, 2025. OssDsign AB (publ.) today announces, through the nomination committee, a revised proposal for election of the board of directors at the annual general meeting on June 11, 2025.In the notice convening the annual general meeting in OssDsign AB (publ) (the “Company”), to be held on 11 June 2025, the nomination committee proposed re-election of Simon Cartmell (also proposed to be re-elected as chairman), Christer Fåhraeus, Jill Schiaparelli and Newton Aguiar, and new-election of David Jern, as ordinary members of the board of directors.   The nomination committee

    OssDsign has carried out a directed share issue of approximately SEK 158 million

    June 3, 2025, 23:04 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) has completed a directed share issue of 11,500,000 shares at a subscription price of SEK 13.75 per share (the “Directed Issue”), through which the Company receives approximately SEK 158 million before deduction of transaction costs. The subscription price was determined based on an accelerated book-building procedure lead by DNB Carnegie Investment Bank AB (“DNB Carnegie”).NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG,

    OssDsign explores the conditions for increasing the scope of the directed share issue to approximately 11.5 million shares

    June 3, 2025, 19:35 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) earlier today informed that the Company has mandated DNB Carnegie Investment Bank AB (“DNB Carnegie”) to evaluate the conditions for carrying out a new share issue of approximately 9 million shares directed towards Swedish and international institutional investors (the “Directed Share Issue”). The interest in participating in the Directed Share Issue has been strong and OssDsign has therefore decided to investigate the conditions for increasing the scope to approximately 11.5 million shares.NOT FOR RELEASE,

    OssDsign explores the conditions to carry out a directed share issue and announces an updated strategy and revised financial targets

    June 3, 2025, 17:31 CEST. OssDsign AB (publ) (”OssDsign” or the ”Company”) intends to explore the conditions to carry out a directed share issue corresponding to approximately nine million shares through an accelerated bookbuilding procedure to Swedish and international institutional investors (the “Directed Issue”), starting immediately. OssDsign has engaged DNB Carnegie Investment Bank AB  (“DNB Carnegie”) to act as Sole Bookrunner in connection with the Directed Issue. In connection with the Directed Share issue, OssDsign announces an updated strategy, “ScaleToProfit”, together with

    OssDsign included in MSCI index

    Uppsala, May 14, 2025. Today, OssDsign AB (publ.) today announces that the company’s share will be included in the MSCI Global Micro Cap Index, implemented as of the close of May 30, 2025.MSCI provides decision support and services to the global investment community and conducts quarterly updates of its equity indexes. In the latest revision, OssDsign has been included in the MSCI Global Micro Cap Index, implemented as of the close of May 30. Based on MSCI’s expertise in research, data and technology, equity indexes of global shares are revised continuously to support clients’ investment

    OssDsign publishes Annual Report 2024

    OssDsign AB (publ) announces that the Annual Report for 2024 is now available as a PDF on the company's website, www.ossdsign.com. A PDF version is also attached to this press release.“Despite operating in a highly competitive market, we have shown there are vast growth opportunities when offering state-of-the-art innovation that solves the clinical challenges” said Morten Henneveld, CEO, OssDsign AB.   For further information, please contact: Morten Henneveld, CEO, OssDsign ABTel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com   Certified Adviser The Company’s

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media